SCHEMBL16332149

SCHEMBL16332149

CC(=O)c1cccc(Nc2nccc3c2cc(-c2ccsc2)n3C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 2/20 0.42
▸ ALDH1A1 P00352 5/20 0.41
▸ CTSC P53634 2/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MAPT P10636 6/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ POLB P06746 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ EGFR P00533 1/20 0.39
▸ TP53 P04637 2/20 0.39
▸ CTSL P07711 1/20 0.39
▸ MAPK1 P28482 3/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ALOX5 P09917 1/20 0.38
▸ PIK3CA P42336 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16331623 0.90 FYN (0.51) FYNCTSCMEN1KMT2AMAPT
SCHEMBL16373491 0.85 FYN (0.46) FYNALDH1A1KMT2AMAPTEGFR
SCHEMBL16373693 0.85 FYN (0.46) FYNCTSCEGFRPIK3CAPRKDC
SCHEMBL16331999 0.83 CTSC (0.44) FYNCTSCMEN1KMT2AMAPT
SCHEMBL16331336 0.83 FYN (0.42) FYNPIK3CAMTORPRKDC
SCHEMBL16332258 0.83 FYN (0.51) FYNALDH1A1MEN1KMT2AMAPT
SCHEMBL16332660 0.82 FYN (0.44) FYNCTSCEGFR
SCHEMBL16332162 0.82 FYN (0.42) FYNMAPK1LMNA
SCHEMBL16332052 0.81 FYN (0.39) FYNMEN1KMT2ANPC1RAB9A
SCHEMBL16332075 0.80 FYN (0.40) FYNNPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US claimed
EP-2818472-A1 Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — EP claimed
US-9458463-B2 Method for treatment of diabetes by a small molecule inhibitor for GRK5 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2016-10-04 — — US disclosed
US-20150079108-A1 KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-03-19 — — US disclosed
WO-2014207260-A1 PYRROLO[3,2-C]PYRIDINE COMPOUNDS AS G-PROTEIN-COUPLED RECEPTOR KINASE 5 (GRK5) MODULATORS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — WO disclosed
EP-2818472-A1 Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-12-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150079108-A1 KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY GCKR, GRK4, GRK5 FYN 574/4885ALDH1A1 4151/4885CTSC 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback